SCHEMBL678617

SCHEMBL678617

Nc1ncnc(Cl)c1C=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.36
HTT P42858 1/20 0.34
NFE2L2 Q16236 1/20 0.34
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.33
KDR P35968 2/20 0.32
PIK3CD O00329 1/20 0.32
ABL1 P00519 1/20 0.32
HCK P08631 1/20 0.32
SRC P12931 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
MTOR P42345 1/20 0.32
PIK3CG P48736 1/20 0.32
EPHB4 P54760 1/20 0.32
PRKDC P78527 1/20 0.32
CHEK1 O14757 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrazine SCHEMBL5282146 0.84 KMT2A (0.37) HTTNFE2L2MEN1ALDH1A1KMT2A
SCHEMBL275155 0.84 KMT2A (0.40) HTTNFE2L2MEN1ALDH1A1KMT2A
SCHEMBL28264362 0.84 LRRK2 (0.36) EGFRLMNAKDRPIK3CDABL1
Phosphine SCHEMBL6066159 0.81 KMT2A (0.39) HTTNFE2L2MEN1ALDH1A1KMT2A
SCHEMBL6066165 0.81 KMT2A (0.39) HTTNFE2L2MEN1ALDH1A1KMT2A
SCHEMBL9942225 0.78 HTT (0.34) HTTNFE2L2
SCHEMBL14414777 0.78 HTT (0.34) HTTNFE2L2
SCHEMBL13243643 0.75 NFE2L2 (0.36) HTTNFE2L2
SCHEMBL11115133 0.74 KDR (0.35) EGFRMEN1ALDH1A1KMT2ALMNA
SCHEMBL4737965 0.74 KDM4E (0.34) EGFRMEN1ALDH1A1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278446-B2 reacting 4-amino-6-chloro-pyrimidine-5-carbaldehyde with 4-benzyloxy-3-chloro-phenylamine in an aqueous solvent and a catalytic amount of hydrochloric acid, to providw 4-amino-6-(4-benzyloxy-3-chloro-phenylamino)-pyrimidine-5-carbaldehyde, then oximination with (2-morpholin-4-yl-ethyl)-hydroxylamine JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-02 US claimed
US-20080249304-A1 PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-09 US claimed
WO-2008073519-A1 PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES JANSSEN PHARMACEUTICA, N.V. (BE) 2008-06-19 WO claimed
US-20260132133-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC (US) 2026-05-14 US disclosed
US-20260042768-A1 PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR INCYTE CORP (US) 2026-02-12 US disclosed
US-12479851-B2 Process and intermediates for preparing a JAK inhibitor INCYTE CORPORATION (US) 2025-11-25 US disclosed
US-20250340559-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE HOLDINGS CORP (US) 2025-11-06 US disclosed
US-12428426-B2 Process and intermediates for preparing a JAK1 inhibitor INCYTE CORPORATION (US) 2025-09-30 US disclosed
US-12247030-B2 Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine INCYTE HOLDINGS CORPORATION (US) 2025-03-11 US disclosed
EP-4511128-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF Kumquat Biosciences Inc. (US) 2025-02-26 EP disclosed
EP-4501410-A2 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS Incyte Holdings Corporation (US) 2025-02-05 EP disclosed
WO-2006135644-A1 AMINOPYRIMIDINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135719-A1 AMINOPYRIMIDINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135718-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281764-A1 AMINOPYRIMIDINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed
US-20060281700-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed
US-20060281755-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS BAUMANN CHRISTIAN A 2006-12-14 US disclosed
EP-0103126-B1 PROCESS FOR PREPARING 4-AMINO-5-DIALKOXYMETHYLPYRIMIDINE DERIVATIVES UBE INDUSTRIES, LTD. (JP) 1987-03-04 EP disclosed
US-4492792-A Process for preparing 4-amino-5-dialkoxy-methylpyrimidine derivatives UBE INDUSTRIES, LTD. (JP) 1985-01-08 US disclosed
EP-0103126-A1 Process for preparing 4-amino-5-dialkoxymethylpyrimidine derivatives UBE INDUSTRIES, LTD. (JP) 1984-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247030-B2 Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine DPYD, TYMS, TYMP EGFR 2936/4885HTT 2048/4885NFE2L2 3109/4885
US-20260042768-A1 PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR JAK1, JAK2, JAK3 EGFR 407/4885HTT 3592/4885NFE2L2 3033/4885
US-20260132133-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KRAS, HRAS, BCL6 EGFR 35/4885HTT 3433/4885NFE2L2 3374/4885
US-12428426-B2 Process and intermediates for preparing a JAK1 inhibitor JAK1, JAK2, JAK3 EGFR 584/4885HTT 2664/4885NFE2L2 1995/4885
US-12479851-B2 Process and intermediates for preparing a JAK inhibitor JAK2, JAK1, JAK3 EGFR 395/4885HTT 3893/4885NFE2L2 2549/4885
US-20250340559-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS JAK3, JAK1, JAK2 EGFR 861/4885HTT 4421/4885NFE2L2 2937/4885
US-20060281764-A1 AMINOPYRIMIDINES AS KINASE MODULATORS FLT3, KIT, TYMP EGFR 146/4885HTT 1981/4885NFE2L2 2845/4885
US-20080249304-A1 PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES DHPS, DPYD, DCPS EGFR 1036/4885HTT 3792/4885NFE2L2 697/4885
US-20060281755-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS FLT3, CSF3R, CSF1R EGFR 223/4885HTT 4487/4885NFE2L2 1267/4885
US-20060281700-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS FLT3, TYMP, PHKG1 EGFR 461/4885HTT 4276/4885NFE2L2 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.